blend5MG
Tesamorelin
5MG Protocol
Tesamorelin 5MG + Ipamorelin 5MG 10MG
Injection Freq.
Once daily
Cycle Sched.
8–16 weeks
Reconstitution
3.0 mL BAC water
Enhanced pulsatile GH secretion via dual‑pathway stimulation
Potential reductions in trunk/visceral fat (tesamorelin data)
Selective GH release with minimal cortisol/ACTH impact (ipamorelin)
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 250 mcg (0.25 mg) | 23 |
| 2 | Weeks 3–4 | 500 mcg (0.5 mg) | 45 |
| 3 | Weeks 5–6 | 1000 mcg (1.0 mg) | 90 |
| 4 | Weeks 7–10 | 1500 mcg (1.5 mg) | 135 |
| 5 | Weeks 11–16 | 2000 mcg (2.0 mg) | 180 |
Once daily
8–16 weeks
This 1:1 blend is designed to intensify endogenous GH pulses by combining upstream pituitary stimulation with a ghrelin‑receptor trigger. Tesamorelin is described as a synthetic GHRH analog that signals the pituitary to release growth hormone. Ipamorelin is a selective GHS‑R1a (ghrelin receptor) agonist that produces a rapid GH pulse but is noted for minimal spillover into cortisol/ACTH/prolactin pathways. The key idea in the protocol is synergy: GHRH analogs and GH secretagogues engage different receptors, and pairing them can yield a larger, more physiologic‑looking GH pulse than either alone. Practically, the blend is positioned for body‑composition support where GH pulsatility is the lever: tesamorelin contributes evidence for visceral/trunk‑fat reduction in clinical contexts, while ipamorelin is used to ‘cleanly’ amplify pulse amplitude. The write‑up emphasizes titration and monitoring because GH/IGF‑1 signaling can also drive edema or joint symptoms in susceptible users.
Injection‑site reactions (erythema, itching/pruritus)
Arthralgia/joint discomfort
Peripheral edema / water retention
Transient flushing
Headache
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)